Form 4: iTeos CMO Disposes of 47,000 RSUs in Merger Transaction

iTeos Therapeutics' Chief Medical Officer, David Feltquate, disposed of 47,000 restricted stock units as part of the company's merger with Concentra Biosciences.

Summary

• David Feltquate, Chief Medical Officer of iTeos Therapeutics, Inc. (ITOS), reported the disposition of 47,000 restricted stock units.
• This transaction occurred on August 29, 2025, as a result of the merger between iTeos Therapeutics, Inc. and Concentra Biosciences LLC.
• Under the merger agreement, eligible restricted stock units vested immediately and were canceled.
• Holders received $10.047 in cash and one non-transferable contractual contingent value right per share for each canceled RSU.
• Following this transaction, David Feltquate's direct beneficial ownership of common stock is 0.

Sentiment

Score: 7

Explanation: The filing reports the successful completion of a merger, which typically represents a positive outcome for the acquired company's shareholders and equity holders, as it provides liquidity and potential future value through CVRs. The transaction is a planned event, not an unexpected negative.

Positives

• The merger with Concentra Biosciences LLC has been completed, indicating a successful acquisition for iTeos shareholders.
• Eligible restricted stock units held by company service providers, including the CMO, vested immediately upon the merger's effective time.
• Holders of canceled restricted stock units received a cash payment of $10.047 per share, providing immediate liquidity.
• The inclusion of a non-transferable contractual contingent value right (CVR) per share offers potential future value based on specific milestones.

Negatives

• The reporting person, David Feltquate, no longer beneficially owns any common stock in iTeos Therapeutics, Inc. following the transaction.
• The company, iTeos Therapeutics, Inc., has been acquired, meaning its independent public trading status has ceased.

Risks

• The value of the contingent value rights (CVRs) is uncertain and depends on future events or milestones, which may not be achieved.
• The non-transferable nature of the CVRs limits liquidity for holders.
• Potential tax implications for the cash consideration received from the canceled restricted stock units.

Future Outlook

The filing indicates the completion of a merger, suggesting iTeos Therapeutics, Inc. will operate as a subsidiary of Concentra Biosciences LLC, and its public trading will cease. The future value for former RSU holders is tied to the contingent value rights.

Management Comments

• Pursuant to the actions of the Compensation and Leadership Development Committee of the Board of Directors of the Company and in accordance with the terms of the Merger Agreement, at the effective time of the Merger, by virtue of the Merger and without any action on the part of the holders, each Company Restricted Stock Unit that was held by a Company service provider who was subject to an individual employment or other agreement and/or a Company severance and change in control plan or agreement that provides for accelerated vesting of time-based equity awards upon the occurrence of a sale of the Company or a qualifying termination of employment or service in connection with, or within a specified time following, a sale of the Company became immediately vested in full.
• Each Accelerated Vesting Restricted Stock Unit that was then outstanding was canceled and, in exchange therefor, the holder of such canceled Company Restricted Stock Unit became entitled to receive in consideration of the cancellation of such Company Restricted Stock Unit (x) an amount in cash without interest, subject to any applicable tax withholding, equal to $10.047 in cash per share and (y) one non-transferable contractual contingent value right per share.

Industry Context

This transaction is typical of consolidation within the biotechnology or pharmaceutical industry, where larger entities acquire smaller, often clinical-stage, companies to gain access to their pipeline, technology, or market position. Mergers often involve a mix of cash and contingent value rights to bridge valuation gaps and share future risks/rewards.

Comparison to Industry Standards

• The use of contingent value rights (CVRs) in M&A transactions is a common mechanism in the biotech industry, particularly when the acquired company's value is heavily dependent on future clinical or regulatory milestones. For example, Sanofi's acquisition of Principia Biopharma included CVRs tied to the approval of tolebrutinib.
• The immediate vesting of equity awards upon a change of control, as seen with the restricted stock units, is a standard provision in executive compensation plans designed to incentivize management through an acquisition process.
• The cash consideration of $10.047 per share for RSUs, alongside CVRs, aligns with typical deal structures in the sector, where a portion of the value is upfront and another is milestone-dependent.

Corporate Governance

Stakeholder Impact

• Shareholders (former): Received cash and CVRs for their shares, providing liquidity and potential future upside.
• Employees (with RSUs): Those with accelerated vesting provisions received immediate vesting and cash/CVR consideration for their RSUs.
• Management (David Feltquate): Disposed of all directly held common stock, receiving cash and CVRs for his RSUs.

Next Steps

• Realization of value from the non-transferable contractual contingent value rights, dependent on future milestones.
• Integration of iTeos Therapeutics into Concentra Biosciences LLC.

Key Dates

Keywords

iTeos Therapeutics, ITOS, Concentra Biosciences, Merger, Acquisition, Restricted Stock Units, RSU, Form 4, Insider Transaction, Contingent Value Right, CVR, Biotechnology, Pharmaceuticals